Flinton Capital Management LLC trimmed its stake in Thermo Fisher Scientific Inc (NYSE:TMO) by 3.4% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 326,978 shares of the medical research company’s stock after selling 11,424 shares during the quarter. Thermo Fisher Scientific accounts for 2.1% of Flinton Capital Management LLC’s portfolio, making the stock its 6th largest position. Flinton Capital Management LLC owned about 0.08% of Thermo Fisher Scientific worth $57,048,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Amalgamated Bank increased its holdings in Thermo Fisher Scientific by 57.0% in the second quarter. Amalgamated Bank now owns 44,921 shares of the medical research company’s stock worth $7,837,000 after buying an additional 16,308 shares during the last quarter. BB&T Securities LLC boosted its position in shares of Thermo Fisher Scientific by 4.4% in the first quarter. BB&T Securities LLC now owns 89,837 shares of the medical research company’s stock valued at $13,798,000 after acquiring an additional 3,819 shares during the period. Mutual of America Capital Management LLC boosted its position in shares of Thermo Fisher Scientific by 2.1% in the second quarter. Mutual of America Capital Management LLC now owns 47,728 shares of the medical research company’s stock valued at $8,327,000 after acquiring an additional 977 shares during the period. Mitchell Capital Management Co. boosted its position in shares of Thermo Fisher Scientific by 40.3% in the second quarter. Mitchell Capital Management Co. now owns 44,940 shares of the medical research company’s stock valued at $7,841,000 after acquiring an additional 12,910 shares during the period. Finally, State Board of Administration of Florida Retirement System lifted its position in Thermo Fisher Scientific by 0.9% in the second quarter. State Board of Administration of Florida Retirement System now owns 580,712 shares of the medical research company’s stock worth $101,317,000 after purchasing an additional 5,213 shares during the period. 83.61% of the stock is owned by institutional investors and hedge funds.
In other news, Director C Martin Harris sold 360 shares of the stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $180.97, for a total value of $65,149.20. Following the completion of the sale, the director now owns 5,312 shares of the company’s stock, valued at $961,312.64. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jim P. Manzi sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 17th. The stock was sold at an average price of $175.20, for a total value of $175,200.00. Following the sale, the director now directly owns 38,757 shares of the company’s stock, valued at approximately $6,790,226.40. The disclosure for this sale can be found here. In the last three months, insiders sold 22,738 shares of company stock valued at $4,021,512. Insiders own 0.49% of the company’s stock.
A number of research analysts have issued reports on TMO shares. Leerink Swann lifted their price objective on Thermo Fisher Scientific from $190.00 to $207.00 and gave the company an “outperform” rating in a report on Monday, October 9th. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $212.00 target price for the company in a research note on Thursday, September 21st. Bank of America Corporation reiterated a “buy” rating and issued a $210.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a research report on Friday, July 21st. Cowen and Company reiterated an “outperform” rating and issued a $220.00 price objective (up from $200.00) on shares of Thermo Fisher Scientific in a research report on Sunday, September 10th. Finally, Deutsche Bank AG set a $226.00 target price on Thermo Fisher Scientific and gave the stock a “buy” rating in a research report on Thursday, October 26th. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $205.71.
Shares of Thermo Fisher Scientific Inc (NYSE TMO) opened at $193.71 on Friday. The stock has a market capitalization of $76,551.63, a price-to-earnings ratio of 21.02, a price-to-earnings-growth ratio of 1.75 and a beta of 1.08. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.26 and a quick ratio of 0.81.
Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 25th. The medical research company reported $2.31 EPS for the quarter, beating the consensus estimate of $2.24 by $0.07. The firm had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $5.03 billion. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. The business’s quarterly revenue was up 13.9% on a year-over-year basis. During the same period last year, the company earned $2.03 earnings per share. equities analysts forecast that Thermo Fisher Scientific Inc will post 9.36 EPS for the current year.
TRADEMARK VIOLATION WARNING: This piece of content was posted by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.com-unik.info/2017/11/04/flinton-capital-management-llc-trims-holdings-in-thermo-fisher-scientific-inc-tmo.html.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).
What are top analysts saying about Thermo Fisher Scientific Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Thermo Fisher Scientific Inc and related companies.